Atlas Trials

Multiple Sclerosis

2,625 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Multiple Sclerosis

RecordFirmDate
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients (NCT00001669)National Institute of Neurological Disorders and Stroke (NINDS)1997-07-01
Prescription Drug Safety and Effectiveness in Multiple Sclerosis (NCT04472975)University of British Columbia1996-01-01
NARCOMS Registry: A Multiple Sclerosis Registry (NCT01018537)University of Texas Southwestern Medical Center1996-01-01
A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple Sclerosis (NCT00004816)National Center for Research Resources (NCRR)1995-07-01
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity (NCT03941184)Mayo Clinic1995-01-01
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple Sclerosis (NCT00004744)National Institute of Neurological Disorders and Stroke (NINDS)1993-02-01
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS) (NCT00001248)National Institute of Neurological Disorders and Stroke (NINDS)1992-07-23
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis (NCT00004814)National Center for Research Resources (NCRR)1991-10-01
Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis (NCT01226654)NYU Langone Health1991-08-01
Optic Neuritis Treatment Trial (ONTT) (NCT00000146)National Eye Institute (NEI)1988-07-01
Longitudinal Optic Neuritis Study (LONS) (NCT00000147)National Eye Institute (NEI)1988-07-01
Assessment of Patients With Multiple Sclerosis (MS) (NCT00001156)National Institute of Neurological Disorders and Stroke (NINDS)1976-01-23
Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis. (NCT01868048)GW Research Ltd
Sleep Disorders in Patients With Multiple Sclerosis (NCT00137904)Groupe Hospitalier Pitie-Salpetriere
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) (NCT00313976)Bayer
Intermediate Expanded Access Protocol CNMAu8.EAP03 (NCT04081714)Clene Nanomedicine
Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis (NCT03822858)Tisch Multiple Sclerosis Research Center of New York
Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron) (NCT00439257)US Department of Veterans Affairs
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease (NCT04540861)Novartis Pharmaceuticals
Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up (NCT00289159)Groupe Hospitalier Pitie-Salpetriere
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis (NCT02807285)Genentech, Inc.
Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis (NCT00043264)National Center for Research Resources (NCRR)
A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis (NCT02317263)University of California, Los Angeles
Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies (NCT01020370)Wayne State University
Electrophysiological Study of Spatiotemporal Gait Parameters in Patients in Early Stage of Multiple Sclerosis (NCT02896933)Fondation Ophtalmologique Adolphe de Rothschild
← Previous

Track Multiple Sclerosis automatically

Every clearance here is in the API, with alerts when new ones post.